This website collects cookies to deliver better user experience. Cookie Policy
Accept
Sign In
The Wall Street Publication
  • Home
  • Trending
  • U.S
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Markets
    • Personal Finance
  • Tech
  • Lifestyle
    • Lifestyle
    • Style
    • Arts
  • Health
  • Sports
  • Entertainment
Reading: Promising Covid-19 Pill Licensed to Nonprofit to Increase Global Supply
Share
The Wall Street PublicationThe Wall Street Publication
Font ResizerAa
Search
  • Home
  • Trending
  • U.S
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Markets
    • Personal Finance
  • Tech
  • Lifestyle
    • Lifestyle
    • Style
    • Arts
  • Health
  • Sports
  • Entertainment
Have an existing account? Sign In
Follow US
© 2024 The Wall Street Publication. All Rights Reserved.
The Wall Street Publication > Blog > Business > Promising Covid-19 Pill Licensed to Nonprofit to Increase Global Supply
Business

Promising Covid-19 Pill Licensed to Nonprofit to Increase Global Supply

Editorial Board Published October 27, 2021
Share
Promising Covid-19 Pill Licensed to Nonprofit to Increase Global Supply
SHARE

The Medicines Patent Pool, which aims to expand poor countries’ access to drugs, will work with multiple drugmakers to produce molnupiravir for 105 nations, including Pakistan, Cambodia and all of Africa, the company and nonprofit said Wednesday.

Contents
Newsletter Sign-upCoronavirus Briefing and Health WeeklyMolnupiravir promises to be the first pill that people infected with Covid-19 could take at home to prevent hospitalization.SHARE YOUR THOUGHTS

How many pills will be produced under the licensing deal once manufacturers’ plants are fully operational is unclear, MPP said, though it predicts some manufacturers will be able to start deliveries this year.

Merck, which developed the drug with Ridgeback Biotherapeutics LP, has said it can manufacture 10 million courses by the end of the year, and is increasing capabilities to make more next year.


Newsletter Sign-up

Coronavirus Briefing and Health Weekly

Get a morning briefing about the coronavirus pandemic three times a week and a weekly Health newsletter when the crisis abates.


“From the beginning we knew we wanted to expand the geographic footprint of our generic partners,” said Paul Schaper, Merck’s executive director of global pharmaceutical public policy. He said Merck’s supply agreements and licensing deals will provide “global access in high-income and low- and-middle income countries at the same time.”

Molnupiravir promises to be the first pill that people infected with Covid-19 could take at home to prevent hospitalization, which would fill a huge gap, including in countries where people lack easy access to basic healthcare.

Wealthy countries, such as Australia and South Korea, have also been waiting for such a drug and have begun reaching supply deals with Merck. The U.S., for instance, has agreed to pay $1.2 billion for 1.7 billion courses, should regulators clear it for use.

The licensing deal is the latest effort designed to avoid the kind of rich-poor split in access that has marked the Covid-19 vaccine rollout, sparking criticism. Many of the countries covered by the licensing deal have limited Covid-19 vaccine supplies.

“Vaccines have been the standout case where people say, ‘This isn’t fair with what’s happening,’” said MPP Executive Director Charles Gore. “This is now a step to correcting some of that.”

Merck previously licensed production of molnupiravir to generic drugmakers in India including Dr. Reddy’s Laboratories Ltd. and Sun Pharmaceutical Industries Ltd.

Molnupiravir promises to be the first pill that people infected with Covid-19 could take at home to prevent hospitalization.

Photo: Merck

The Bill & Melinda Gates Foundation recently pledged up to $120 million to accelerate manufacturing of generic forms of molnupiravir for lower-income countries.

Altogether, the deals mean Merck would end up making molnupiravir largely for wealthier countries, while smaller drugmakers will produce the bulk of pills for low- and middle-income countries.

Molnupiravir promises to be a long-awaited addition to the Covid-19 medicine chest.

While drugs such as a steroid named dexamethasone and the antiviral remdesivir have been found to reduce the length of hospitalization, only antibody drugs have been shown to help keep people out of the hospital.

Yet the antibody drugs must be given by intravenous infusion at a doctor’s office, hospital or medical clinic, and they have been in short supply in many countries.

Merck and Ridgeback asked the U.S. Food and Drug Administration to authorize the pill this month, after a late-stage study showed it cut the risk of hospitalization or death by about 50% in high-risk people with mild to moderate Covid-19.

Under the licensing deal, Merck, Ridgeback and Emory University—where researchers invented the drug—will forgo royalties.

Generic companies will ask MPP for permission to produce molnupiravir, with MPP selecting multiple manufacturers that would strike supply deals with countries, Mr. Gore said.

About 50 companies have informally expressed interest in producing the drug so far, Mr. Gore said. He declined to name them.

SHARE YOUR THOUGHTS

To what extent will access to a Covid-19 pill help the people and the economies of low-income countries? Join the conversation below.

Competition among the manufacturers is expected to make the pill affordable. Research suggests that such a licensing arrangement could reduce the cost of molnupiravir to less than $20 a course of treatment, Mr. Gore said.

Increasing manufacturing shouldn’t be difficult because molnupiravir is a small molecule, which companies have made for years, Mr. Gore said.

The Gates funding will help manufacturers implement a simplified medicine-making process and gather data to apply for regulatory approvals, said Trevor Mundel, the foundation’s president of global health.

The foundation worked with chemists to simplify molnupiravir’s manufacturing process to two steps from about a dozen, Dr. Mundel said.

Some larger generics manufacturers could produce each month as many as 10 million treatment courses, meaning 40 capsules of 200 milligrams each, Dr. Mundel said.

The funding, he said, could “provide some kind of bridge and to get everybody to the state of using the simplest synthesis and getting the most affordable quality product out there.”

Write to Jared S. Hopkins at [email protected] and Betsy McKay at [email protected]

Copyright ©2021 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

TAGGED:Business NewsPAIDWall Street Publication
Share This Article
Twitter Email Copy Link Print
Previous Article Cutting Emissions Remains a Struggle for Shipping Cutting Emissions Remains a Struggle for Shipping
Next Article Actress Charlize Theron pushes for global COVID-19 vaccine sharing Actress Charlize Theron pushes for global COVID-19 vaccine sharing

Editor's Pick

Alyssa Farah Griffin: ‘The View’ Co-Host is Pregnant With Child #1!

Alyssa Farah Griffin: ‘The View’ Co-Host is Pregnant With Child #1!

Studying Time: 3 minutes The View co-host Alyssa Farah Griffin is pregnant! On ‘The View,’ Alyssa Farah Griffin breaks the…

By Editorial Board 3 Min Read
Melissa Rycroft Admits to Actually “Struggling” in Wake of DUI Arrest
Melissa Rycroft Admits to Actually “Struggling” in Wake of DUI Arrest

Studying Time: 3 minutes Melissa Rycroft is in a darkish place proper…

4 Min Read
Amy Duggar Describes Studying Grandfather Was a ‘Predator’
Amy Duggar Describes Studying Grandfather Was a ‘Predator’

Studying Time: 4 minutes Amy Duggar King grew up figuring out and…

6 Min Read

Oponion

Opinion: Newsom should shield California’s ingesting water from microplastics

Opinion: Newsom should shield California’s ingesting water from microplastics

Within the present political surroundings, the place good theater typically…

September 12, 2025

Trump is again on his insane ‘rigged election’ bullsh-t

We’ll give him this: President Donald…

June 19, 2025

10 Greatest Cremo Colognes For Males – Favourite Scents For 2024 | Fashion

If you happen to’re in the…

October 10, 2024

Los Gatos neighborhood middle challenge makes progress

Creating neighborhood Group engagement stays excessive…

November 25, 2024

Newsom units apart politics for wildfire help—regardless of Trump’s childishness

Democratic Gov. Gavin Newsom of California…

February 6, 2025

You Might Also Like

FundRelis Restora Brings Accountability to the Wild West of Online Scams
BusinessTrending

FundRelis Restora Brings Accountability to the Wild West of Online Scams

Zurich, Switzerland — In a financial era defined by digital innovation and unregulated trading, a quiet revolution is taking shape inside…

5 Min Read
Russia for Business: Experts Who Help Drive Decisions
BusinessTrending

Russia for Business: Experts Who Help Drive Decisions

Amid sanctions and the restructuring of global supply chains, understanding the logic behind Russia’s actions has become a practical necessity…

4 Min Read
The Quiet Shift in America’s Workforce: Why Side Hustles Are Becoming Essential for Women Over 40
BusinessTrending

The Quiet Shift in America’s Workforce: Why Side Hustles Are Becoming Essential for Women Over 40

Across the nation, a quiet but powerful workforce shift is underway. Increasingly, women over 40 are seeking side hustles to…

4 Min Read
Thales Reinforces its Management in eSIM and IoT Connectivity with a ‘Ready to Use’ Licensed Resolution
Business

Thales Reinforces its Management in eSIM and IoT Connectivity with a ‘Ready to Use’ Licensed Resolution

At a time when billions of linked objects are reshaping industries, Thales has achieved a vital safety certification for its…

4 Min Read
The Wall Street Publication

About Us

The Wall Street Publication, a distinguished part of the Enspirers News Group, stands as a beacon of excellence in journalism. Committed to delivering unfiltered global news, we pride ourselves on our trusted coverage of Politics, Business, Technology, and more.

Company

  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • WP Creative Group
  • Accessibility Statement

Contact

  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability

Term of Use

  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices

© 2024 The Wall Street Publication. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?